Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Haematologica|March 10, 2022
The IL32/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibitionSalomé Decombis, Antonin Papin, Céline Bellanger, et al.
Oncotarget|October 17, 2018
Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignanciesPatrice Chevallier, Pierre Peterlin, Alice Garnier, et al.
Cancers|September 3, 2020
Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1β and JAK2V617F-Independent Cytokines in Myeloproliferative NeoplasmsSophie Allain-Maillet, Adrien Bosseboeuf, Nicolas Mennesson, et al.
British Journal of Haematology|November 9, 2018
A novel complete blood count-based score to screen for myelodysplastic syndrome in cytopenic patientsRobin Boutault, Pierre Peterlin, Marouane Boubaya, et al.
Hemasphere|August 28, 2023
Targeted High-throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in FranceMeryl Darlington, Pierre Sujobert, Olivier Kosmider, et al.
Ejhaem|July 18, 2022
RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutationBaptiste Le Calvez, Yannick Le Bris, Guillaume Herbreteau, et al.
Hemasphere|November 15, 2019
The Need for a Consensus Next-generation Sequencing Panel for Mature Lymphoid MalignanciesPierre Sujobert, Yannick Le Bris, Laurence de Leval, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 1, 2019
Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid MalignanciesLouise Bouard, Thierry Guillaume, Pierre Peterlin, et al.
European Journal of Haematology|April 4, 2017
Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?Elsa Lestang, Pierre Peterlin, Yannick Le Bris, et al.
Blood|August 10, 2023
CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphomaSalomé Decombis, Celine Bellanger, Yannick Le Bris, et al.
Pageof 4